10x Genomics, Inc.
Background
10x Genomics, Inc. is an American biotechnology company specializing in gene sequencing technologies for scientific research. Founded in 2012 by Serge Saxonov, Ben Hindson, and Kevin Ness, the company is headquartered in Pleasanton, California. Its mission is to deliver powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology to advance human health. The company's innovative single-cell, spatial, and in situ technologies have been cited in over 10,000 research papers, enabling discoveries across oncology, immunology, neuroscience, and more.
Key Strategic Focus
10x Genomics focuses on providing advanced genomic analysis solutions, emphasizing single-cell and spatial genomics. Core objectives include enabling high-resolution analysis of biological systems, facilitating a deeper understanding of complex diseases, and advancing precision medicine. The company's primary areas of specialization encompass single-cell transcriptomics, single-cell genomics, single-cell epigenomes, linked-reads genomics, and spatial transcriptomics. Key technologies utilized include the Chromium Single Cell platform, Visium Spatial platform, and Xenium In Situ platform. Primary markets targeted are academic and translational researchers, as well as biopharmaceutical companies.
Financials and Funding
As of July 29, 2025, 10x Genomics' stock price is $14.64 USD. The company has an estimated annual revenue of $459.2 million and a valuation of approximately $11.6 billion. Total funding raised amounts to $242.6 million. The company operates on a business model that includes product sales, service contracts, collaborations, and intellectual property licensing.
Pipeline Development
10x Genomics offers a range of products designed to advance genomic research:
- Chromium Single Cell Platform: Enables high-throughput single-cell analysis, facilitating transcriptomic profiling and multiomic studies.
- Visium Spatial Platform: Allows spatial gene expression analysis, providing insights into tissue architecture and gene expression patterns.
- Xenium In Situ Platform: Offers single-cell spatial imaging, enabling the study of gene expression within tissue sections.
These platforms are utilized in various research areas, including oncology, immunology, and neuroscience.
Technological Platform and Innovation
10x Genomics' technological platforms include:
- Chromium Single Cell Platform: Facilitates high-throughput single-cell analysis, enabling comprehensive transcriptomic profiling.
- Visium Spatial Platform: Provides spatial gene expression analysis, allowing researchers to map gene activity within tissue sections.
- Xenium In Situ Platform: Delivers single-cell spatial imaging, offering insights into gene expression at the tissue level.
These platforms are supported by proprietary technologies and scientific methodologies, including microfluidics, biochemistry, mechanical engineering, computational biology, and software development. The company's integrated solutions are designed to analyze biological systems at a resolution that matches the complexity of biology.
Leadership Team
- Serge Saxonov: Co-founder and CEO. Prior to founding 10x Genomics, Serge was the founding architect and director of research and development at 23andMe.
- Ben Hindson: Co-founder and President, Chief Scientific Officer. Ben has a background in molecular biology and has contributed significantly to the development of 10x Genomics' technologies.
- Justin McAnear: Chief Financial Officer. Justin joined 10x Genomics in 2018, bringing experience from his previous role as Tesla's finance chief.
Market Insights and Dynamics
The global single-cell genomics market was estimated to reach $630 million in 2019, with projections to grow at 23% annually, potentially reaching close to $1.5 billion by 2023.
Competitor Analysis
Key competitors in the genomics space include:
- Illumina: Dominant in next-generation sequencing (NGS), offering comprehensive solutions for large-scale genomic studies.
- Bio-Rad Laboratories: Specializes in life science research and clinical diagnostics, with innovations in genomics, particularly in PCR and gene editing.
- Fluidigm: Focuses on single-cell genomics and mass cytometry, providing high-throughput protein and gene expression analysis.
- NanoString Technologies: Offers life science tools for translational research and molecular diagnostics, including spatial transcriptomics.
- BGI Group: A leading genomics organization based in China, known for extensive sequencing capabilities and research collaborations.
Strategic Collaborations and Partnerships
In July 2025, 10x Genomics signed a partnership with the A*STAR Genome Institute of Singapore for the Target Inference from Spatialomics and Histology Using Multimodal AI & Phenotypes (TISHUMAP) project.
Operational Insights
10x Genomics operates in a competitive landscape, with its primary competitors being Illumina, Bio-Rad Laboratories, Fluidigm, NanoString Technologies, and BGI Group. The company differentiates itself through its focus on single-cell and spatial genomics, offering integrated solutions that enable high-resolution analysis of biological systems. Its technological platforms, such as the Chromium Single Cell, Visium Spatial, and Xenium In Situ platforms, provide comprehensive tools for researchers in various fields, including oncology, immunology, and neuroscience.
Strategic Opportunities and Future Directions
10x Genomics is well-positioned to capitalize on the growing demand for single-cell and spatial genomics solutions. The company's strategic roadmap includes expanding its product offerings, enhancing technological capabilities, and forming strategic partnerships to strengthen its market position. By leveraging its innovative platforms and expertise, 10x Genomics aims to advance scientific discoveries and contribute to the advancement of human health.
Contact Information
- Official Website: www.10xgenomics.com
- Social Media Profiles:
- Twitter: @10xgenomics
- LinkedIn: 10x Genomics
- Facebook: 10x Genomics
- Instagram: @10xgenomics
